Keros Therapeutics Triggers $10M Milestone with Phase III RENEW Trial Start
Keros Therapeutics and Takeda dosed the first patient in a Phase III RENEW trial evaluating elritercept for anemia and thrombocytopenia in MDS, triggering a $10 million milestone payment. Elritercept competes with Bristol Myers’ Reblozyl, which has over $2.3 billion in sales, and Geron’s Rytelo in the low- to intermediate-risk MDS market.
1. Phase III RENEW Trial Initiation
Keros Therapeutics, in partnership with Takeda, has initiated the RENEW trial, a global Phase III study of elritercept in very low-, low- and intermediate-risk MDS patients with anemia and thrombocytopenia. The trial’s primary endpoints are reduction in transfusion burden and improvement in blood counts across patient cohorts.
2. Takeda Partnership and Milestone
Dosing the first patient triggered a $10 million milestone payment under the global licensing agreement, providing non-dilutive capital for Keros. Further milestones and tiered royalties are expected upon interim readouts, regulatory submissions, and commercial launch.
3. Competitive Landscape
Elritercept is positioned to compete with Bristol Myers’ Reblozyl, which has annualized sales above $2.3 billion, and Geron’s Rytelo, which generated $183.6 million in 2025. Its novel mechanism targeting aberrant cytokine signaling may offer differentiation in both anemia and thrombocytopenia settings.
4. Outlook and Market Potential
Successful Phase III results and subsequent regulatory approvals could expand Keros’ footprint in the MDS market, currently dominated by erythropoiesis-stimulating agents and growth-factor therapies. The RENEW trial data will inform launch preparation and potential partnerships for commercial distribution.